Operator: Good morning, my name is Sammy, and I will be your conference operator today. At this time, I would like to welcome everyone to the United Therapeutics Corporation Fourth Quarter and Annual 2012 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session.
Remarks today concerning United Therapeutics will include forward-looking statements, which represent United Therapeutics' expectations or beliefs regarding future events based on current assumptions. United Therapeutics cautions that such statements involve risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements.
Consequently, all such forward-looking statements are qualified by the cautionary language and risk factors set forth in the United Therapeutics' periodic and other reports filed with the SEC. There can be no assurance that the actual results, events or developments referenced in such forward-looking statements will occur or be realized. United Therapeutics assumes no obligations to update these forward-looking statements to reflect actual results, changes in assumptions or changes in factors affecting such forward-looking statements.
Thank you. Dr. Rothblatt. You may begin.
Martine A. Rothblatt, Ph.D. - Chairman and CEO: Thank you operator. Good morning everybody on the conference call. I am joined this morning by John Ferrari our Chief Financial Officer, Roger Jeffs our President and Chief Operating Officer and Andy Fisher our Chief Strategy Officer and individual in-charge of legal and Investor Relations. I'd like to start by making a few introductory remarks and then welcome any questions that could be directed to Andy, Roger, John or myself.
The press release that we issued this morning certainly make this about as joyful a quarterly and annual conference call, as any CEO could ask for. We're reporting a record revenues, record profits per share, so across the board it's just been a fantastic quarter and a fantastic year for United Therapeutics. Our excellent annual results reflect both our leadership in pulmonary hypertension medicines and our discipline in focusing Company resources on transformative growth opportunities.
One of the things which is especially noteworthy is that as of the end of 2012, our medicines are now being prescribed to more pulmonary hypertension patients in the United States than any other companies medicine, that's a high watermark that we've achieved after our several years striking about against other companies, which are much larger and better capitalized than we. I think the reason for this is completely due to the fact that physicians over time have found that the United Therapeutics medicines are the once that they rely on to provide superior results for their patients. Let me briefly mention what those medicines are. Briefly mention some of their key highlights, and then say a word or two about our pipeline and then move into question-and-answers.